COMP <GO>
MTD vs ABBV // RSI-14 & 200D SMA MOMENTUM
Mettler-Toledo International Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: MTD 8
— ABBV 6
▲ RSI-14 & 200D SMA MOMENTUM LEADER: MTD
LAST: $1,718.61 (+1.19%) • MKT CAP: $34.44B
rsi-technicals
70.6
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
rsi-technicals
65.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MTD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MTD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.40% | 70.20% | -10.80 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 30.40% | 29.00% | +1.40 | MTD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.7x | 33.3x | -1.60 | MTD | /valuation <GO> |
| Free Cash Flow Yield | 2.46% | 3.47% | -1.01 | ABBV | /fcf-yield <GO> |
| Operating Margin | 26.30% | 24.60% | +1.70 | MTD | /operating-margins <GO> |
| Net Profit Margin | 21.60% | 6.90% | +14.70 | MTD | /net-margins <GO> |
| Revenue Growth (YoY) | 4.00% | 8.60% | -4.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.09 | 5.33 | +5.76 | MTD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | MTD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 70.6 | 65.1 | +5.50 | MTD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 1.15 | -0.28 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.8x | 113.1x | -76.30 | MTD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $34.44B | $513.86B | -$479.43B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MTD REV | ABBV REV | MTD GROSS % | ABBV GROSS % | MTD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.03B | $61.16B | 59.4% | 70.2% | $848.6M | $17.82B |
| FY 2024 | $3.87B | $56.33B | 60.1% | 70.0% | $864.4M | $17.83B |
| FY 2023 | $3.79B | $54.32B | — | — | $795.4M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MTD // BETA 0.87
ABBV // BETA 1.15